Advances in Automated Insulin Delivery with the Medtronic 780G: The Australian Experience
Authors' conclusion
Real-world data from Australia shows that a higher proportion of MiniMed 780G users meet clinical targets for CGM consensus metrics compared to MiniMed 670/770G users and glucose control was sustained over 12 months.
Study context
- Population
- Australians with T1D using MiniMed systems
- Participants
- 3,566 vs 5,676
- Exposure
- MiniMed 780G vs MiniMed 670/770G
- 780Gn = 3,566
- 670/770Gn = 5,676reference
- Outcome
- TIR (70-180 mg/dL)
Methodological detailsdeidentified Carelink continuous glucose monitoring (CGM) data, January 2020 to December 2022, Follow-up: 670/770G 364 ± 244 days; 780G 146 ± 145 days (mean ± SD)
- Deidentified Carelink CGM data
- January 2020 to December 2022
- Follow-up: 670/770G 364 ± 244 days; 780G 146 ± 145 days (mean ± SD)
Main finding
As reported in the abstract
P < 0.001
Observational data: associations, not effects.
Further findings
Attaining all three CGM targets (GMI <7.0%, TIR >70%, TBR <4%) · higher with 780G
P < 0.001
Mean
| Outcome | 780G | 670/770G | P value |
|---|---|---|---|
| TARLower with 780G | 25.5% (SD 10.9%) | 30.6% (SD 11.7%) | P < 0.001 |
| GMILower with 780G | 6.9% (SD 0.4%) | 7.2% (SD 0.4%) | P < 0.001 |
Transition from 670/770G to 780G (n = 1051): TIR and time above range (TAR)
- TIR increased (P < 0.001)
- 70.0% ± 10.7% to 74.0% ± 10.2%
- TAR decreased (P < 0.001)
- 28.1% ± 10.9% to 24.0% ± 10.7%
- TBR unchanged
- CGM metrics stable at 12 months post-transition
Safety
Mean
| Outcome | 780G | 670/770G | P value |
|---|---|---|---|
| TBR (<70 mg/dL) | 1.9% (SD 1.8%) | 2.0% (SD 1.8%) | P = 0.0015 |
Original publication
Advances in Automated Insulin Delivery with the Medtronic 780G: The Australian Experience. Diabetes Technol Ther. Published 1 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →